Nivolumab ( optidov ), for Clinical, Hospital, Personal, Packaging Type : Bottles

Listing ID #5915452

Nivolumab indicated for the treatment of patients with:

BRAF V600 wild-type unresectable or metastatic melanoma, as a single agent.

BRAF V600 mutation-positive unresectable or metastatic melanoma, as a single agent.

Unresectable or metastatic melanoma, in combination with ipilimumab.

Metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

Advanced renal cell carcinoma who have received prior anti-angiogenic therapy.

Classical Hodgkin lymphoma (adult patients) that has relapsed or progressed after: